Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 7.00 |
Expiry date | 2024-05-17 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 49 |
RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 79,575 shares, and restricted stock units (RSUs) covering an aggregate of 42,400 shares, of BioCryst common stock. The options and RSUs were granted as of April 30, 2024, as inducements material to each employee entering into employmen
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.